TRIP12

Across TCGA pan-cancer cohorts, TRIP12 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRIP12 data layer compared with 25 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TRIP12 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TRIP12 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

PDAC, HNSC, and OV are the cancer types where TRIP12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.743	0.902	.009	21	view →
HNSC	DFS	Median	IV	0.792	0.519	.004	19	view →
OV	DFS	Tertile	All	0.437	1.000	.005	16	view →
LUAD	DFS	Quartile	All	0.356	0.833	.008	12	view →
UCEC	DFS	Tertile	II,III,IV	0.808	0.301	.033	10	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRIP12–PDAC (OS)

Open the PDAC breakdown →